aav 8 rh 3bnc117 igg1 ls vector (Vector Laboratories)
Vector Laboratories is a verified supplier 
Vector Laboratories manufactures this product 
96
Structured Review
Vector Laboratories
aav 8 rh 3bnc117 igg1 ls vector
Aav 8 Rh 3bnc117 Igg1 Ls Vector, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 561 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/Goat+IgG+(Control+Antibody)/pmc12460164-56-8-9
Average 96 stars, based on 561 article reviews
Aav 8 Rh 3bnc117 Igg1 Ls Vector, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 561 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/Goat+IgG+(Control+Antibody)/pmc12460164-56-8-9
Average 96 stars, based on 561 article reviews
aav 8 rh 3bnc117 igg1 ls vector - by Bioz Stars,
2026-11
96/100 stars
Images
1) Product Images from "Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life"
Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life
Journal: Nature
doi: 10.1038/s41586-025-09330-2
Figure Legend Snippet: a , The three infants in Group 1 were treated intramuscularly (IM) at birth with the indicated dose of an AAV-1 vector expressing rh-eCD4-IgG2-LS. b , The three infants in Group 2 were treated intravenously (IV) at birth with the indicated dose of an AAV-8 vector expressing rh-eCD4-IgG2-LS. Four weeks later, the Group 2 macaques were injected IM with the same dose of the same AAV-1/rh-eCD4-IgG2-LS vector administered to the Group 1 animals. c , The three infants in Group 3 were injected IM at birth with the indicated dose of an AAV-8 vector expressing rh-3BNC117-IgG1-LS. As the nine infants in Groups 1–3 approached 20 weeks of age, a per-protocol transition to paired housing necessitated the removal of one animal from the study. Because serum concentrations of rh-3BNC117-IgG1-LS had fallen below detection limits after week 12 in the Group 3 infant rh3-3, this animal was removed from the study. d , The six AAV vector-naïve infants in Group 4 were matched in age to those in Groups 1–3. Beginning at postnatal weeks 30–34, all the AAV-treated RMs in Groups 1–3 (except for rh3-3) and the Group 4 controls were subjected to weekly oral challenges with escalating doses of SHIV-AD8 EO .
Techniques Used: Plasmid Preparation, Expressing, Injection
Figure Legend Snippet: a – i , Serum concentrations of rh-eCD4-IgG2-LS ( a – f ) or rh-3BNC117-IgG1-LS ( g – i ) and ADA levels ( a – i ) in infant rhesus macaques in group 1 (rh1-1 ( a ), rh1-2 ( b ) and rh1-3 ( c )), group 2 (rh2-1 ( d ), rh2-2 ( e ) and rh2-3 ( f )), and group 3 (rh3-1 ( g ), rh3-2 ( h ) and rh3-3 ( i )). ADA responses for groups 1–3 are depicted as the serum immunoglobulin reactivity (absorbance values at 450 nm ( A 450 nm )) against plate-bound rh-eCD4-IgG2-LS or rh-3BNC117-IgG1-LS. j , Kaplan–Meier analysis of SHIV acquisition in each experimental group (groups 1–3) versus the control group (group 4) after oral challenges with increasing doses of SHIV-AD8 EO expressed as Gag p27 content. P values were calculated using the Mantel–Cox test. k , l , log 10 -transformed plasma viral loads in the group 4 macaques ( n = 6) ( k ) and in the only group 1 ( l ) monkey (rh1-1) that acquired infection. Empty red bars in l indicate the post-infection serum rh-eCD4-IgG2-LS concentrations.
Techniques Used: Control, Transformation Assay, Clinical Proteomics, Infection
![Sera from the macaques in Group 1 (a-c) , Group 2 (d-f) , and Group 3 (g,h) were tested for their ability to neutralize the in vitro infectivity of SHIV-AD8 EO in TZM-bl cells. Neutralizing titers [i.e., inhibitory dilutions at which 50% of neutralization (ID 50 ) was observed] were derived from these assays and plotted against the right y-axis of each panel. As a reference, the serum concentrations of rh-eCD4-IgG2-LS ( a-f ) or rh-3BNC117-IgG1-LS ( g,h ) were plotted against the left y-axis. Sera from the Group 3 macaque rh3-3 were not assayed for anti-SHIV-AD8 EO neutralizing antibodies because this animal was euthanized before the start of the oral SHIV challenge phase (gray shaded boxes).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0164/pmc12460164/pmc12460164__41586_2025_9330_Fig7_ESM.jpg "... serum concentrations of rh-eCD4-IgG2-LS ( a-f ) or rh-3BNC117-IgG1-LS ( g,h ) were plotted against the left ...")
Figure Legend Snippet: Sera from the macaques in Group 1 (a-c) , Group 2 (d-f) , and Group 3 (g,h) were tested for their ability to neutralize the in vitro infectivity of SHIV-AD8 EO in TZM-bl cells. Neutralizing titers [i.e., inhibitory dilutions at which 50% of neutralization (ID 50 ) was observed] were derived from these assays and plotted against the right y-axis of each panel. As a reference, the serum concentrations of rh-eCD4-IgG2-LS ( a-f ) or rh-3BNC117-IgG1-LS ( g,h ) were plotted against the left y-axis. Sera from the Group 3 macaque rh3-3 were not assayed for anti-SHIV-AD8 EO neutralizing antibodies because this animal was euthanized before the start of the oral SHIV challenge phase (gray shaded boxes).
Techniques Used: In Vitro, Infection, Neutralization, Derivative Assay
Figure Legend Snippet: a – j , The AAV-8-rh-3BNC117-IgG1-LS vector was administered to rhesus macaques across four age groups: group 5 ( a , b ; 48 h, except for rh5-6 (see below)); group 6 ( c , d ; approximately 2 years); group 7 ( e , f ; 4 weeks); group 8 ( g , h ; 8 weeks); and group 9 ( i , j ; 12 weeks). LLOQ, lower limit of quantification. a , c , e , g , i , Serum rh-3BNC117-IgG1-LS concentrations. b , d , f , h , j , Anti-rh-3BNC117-IgG1-LS responses, or ADAs, in each group. k , Serum concentrations of rh-3BNC117-IgG1-LS at week 20 in the group 5 newborns ( n = 5) and group 6 juveniles ( n = 6). l , Comparison of cumulative levels of ADAs produced by the group 5 newborns and group 6 juveniles during the 20 weeks of follow-up. AUC, area under the curve. In k , l , the group 5 infant rh5-6 was not included in the comparisons because it received the AAV-8-rh-3BNC117-IgG1-LS vector 4 weeks after birth. m , Monkeys in groups 3 and 5–9 were divided into three age brackets and their serum rh-3BNC117-IgG1-LS concentrations at week 20 were compared. In k – m , bars correspond to medians and P values were two-sided and calculated using the Mann–Whitney U -test. P values in brackets were calculated without the group 6 outlier rh6-6. n , Correlation between the age (in weeks) of each monkey at the time of AAV inoculation and serum rh-3BNC117-IgG1-LS concentration at week 20.
Techniques Used: Plasmid Preparation, Comparison, Produced, MANN-WHITNEY, Concentration Assay
Figure Legend Snippet: Total IgG reactivity to the AAV-8 capsid was measured by ELISA using a fixed dilution (1:1,000) of serum collected at baseline (day 0) and every two weeks thereafter until the last follow up at week 20. All samples from the Group 5 ( n = 6; a ) and Group 6 ( n = 6; b ) animals were tested in the same 384-well ELISA plate and the absorbance values measured at 450 nm for each sample were plotted against time. c , Geometric means of absorbance values measured for Group 5 (yellow hexagons) and Group 6 (gray hexagons) were plotted against time. The two-sided P value was calculated using the Mann-Whitney U test and resulted from comparing Groups 5 and 6 in terms of their cumulative levels of anti-AAV-8 IgG reactivity (area under curve analysis of absorbance values) measured over the 20 weeks of follow-up.
Techniques Used: Enzyme-linked Immunosorbent Assay, MANN-WHITNEY
Figure Legend Snippet: Sixteen pregnant female rhesus macaques at similar gestational stages were selected on the basis of having little or no serum reactivity to AAV-8 by ELISA. These animals were then divided into three groups depending on whether they were treated with recombinant forms of rh-3BNC117-IgG1. The Group A dams ( n = 8) received no bNAb infusion and underwent cesarean (c)-section when their pregnancies reached term at gestational week 24. The only exceptions were dams rhA-1 and rhA-3, which delivered their babies vaginally ahead of schedule. The dams in Groups B and C ( n = 4 each) were treated intravenously with 30 mg/kg of recombinant rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1, respectively, at gestational week 22 and then underwent c-section two weeks later. The offspring of the dams in Groups A-C were transferred to the nursery after birth and then assigned to Groups 7–11. The infants in Groups 7–11 were treated intramuscularly (IM) with 2.0 × 10 12 genome copies ml –1 of an AAV-8/rh-3BNC117-IgG1-LS vector at postnatal weeks 4, 8, or 12, as depicted.
Techniques Used: Enzyme-linked Immunosorbent Assay, Recombinant, Plasmid Preparation
Figure Legend Snippet: a-h , Serum concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in the Group B (a-d) and Group C (e-h) dams following passive infusion of 30 mg/kg these molecules at gestational week 22 (vertical dotted lines). Two weeks later, pregnancies reached term and the animals underwent cesarean (c)-section (vertical solid line). The last two weeks of pregnancy are indicated by a gray box. i , Table listing the concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in maternal, cord blood, or newborn serum at the time of c-section.
Techniques Used:
Figure Legend Snippet: While the macaques in groups 10 and 11 were in their final weeks of gestation, their mothers were treated intravenously with recombinant rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1, leading to transplacental transfer of these molecules. The macaques that were prenatally exposed to the bNAb were delivered two weeks later and then treated with the AAV-8-rh-3BNC117-IgG1-LS vector at 8 weeks (group 10) or 12 weeks (group 11) of age. a , c , Serum rh-3BNC117-IgG1-LS concentrations in group 10 ( a ) and group 11 ( c ). ADAs were assessed as described in Fig. for group 10 ( b ) and group 11 ( d ). All samples from groups 7–11 were screened for anti-rh-3BNC117-IgG1-LS antibodies in the same 384-well enzyme-linked immunosorbent assay (ELISA) plate. e , f , Cumulative serum rh-3BNC117-IgG1-LS concentrations ( e ) and ADA levels (absorbance values of anti-rh-3BNC117-IgG1-LS reactivity in serum) ( f ) measured over the first 20 weeks post-intervention were compared between infant macaques exposed to recombinant forms of rh-3BNC117-IgG1 in utero (groups 10 and 11) and age-matched bNAb-naive infants (groups 8 and 9). Bars correspond to medians. All P values were two-sided and calculated using the Mann–Whitney U -test.
Techniques Used: Recombinant, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, In Utero, MANN-WHITNEY
Figure Legend Snippet: Four out of the seven AAV-treated macaques in groups 1–3 that resisted oral challenges with SHIV-AD8 EO were kept alive for up to four years, and AAV-driven transgene expression in serum was monitored. These macaques were not re-dosed with AAV vectors after the neonatal period. a – d , Serum concentrations of rh-3BNC117-IgG1-LS ( a , b ) or rh-eCD4-IgG2-LS ( c , d ) and NAb titres against SHIV-AD8 EO for rh3-1 ( a ), rh3-2 ( b ), rh1-2 ( c ), and rh2-3 ( d ). Date of birth (DOB) and date of the last rh-3BNC117-IgG1-LS or rh-eCD4-IgG2-LS measurement are shown. ID 50 , half-maximal infectious dose. e – i , The six macaques in group 5 were kept alive beyond the 20-week follow-up period described in Fig. and their serum concentrations of rh-3BNC117-IgG1-LS ( e ) and NAb titres against SHIV-AD8 EO ( f ) were monitored until the animals reached approximately 2.5 years of age. Beginning at weeks 133–140 post-intervention, the group 5 monkeys and six controls (group 12) were subjected to repeated intrarectal (IR) challenges with a fixed marginal dose of SHIV-AD8 EO . g , Kaplan–Meier analysis of SHIV acquisition in groups 5 and 12. The P value was calculated using the Mantel–Cox test. h , i , Plasma viral loads in the group 12 macaques ( n = 6) ( h ) and in the only group 5 monkey (rh5-2) ( i ) that acquired infection.
Techniques Used: Expressing, Clinical Proteomics, Infection
Related Articles
other:Article Title: Table 3 Article Snippet: Anti-goat IgG , Rabbit , 1:200 , , Article Title: Antimicrobial therapy combined with C-C chemokine receptor type 2 modulation dampens mycobacteria-aggravated monocyte activation and atherosclerosis Article Snippet: We also assessed triggering receptor expressed on myeloid cells 2 (TREM2 + ) content in atherosclerotic lesions with anti-TREM2 antibody at 1:125 dilution (goat IgG, A84373 , antibodies.com), using VECTASTAIN® Elite® ABC-HRP kit, Peroxidase (goat IgG, PK-6105, Vector Labs) and ImmPACT® DAB substrate kit, Peroxidase ( Article Title: Table 2 Article Snippet: Anti-goat IgG , 1:5000 , Article Title: Article Snippet: Anti-Goat IgG (H + L), made in Incubation:Article Title: Connectivity of the Superior Temporal Polysensory Area With the Presubiculum, Parasubiculum, Entorhinal Cortex, and Claustrum–Endopiriform Complex in the Common Marmoset ( Callithrix jacchus ) Article Snippet: To visualize CTB‐labeled cells by immunohistochemistry, the sections were first incubated overnight at 4°C in Tris‐buffered saline (TBS) containing 2% normal rabbit serum and 0.5% Triton X‐100, and then incubated for 48 h at 4°C with goat anti‐CTB (1:30,000 or 1:60,000; List Biological Laboratories; Table ), 1% normal rabbit serum, and 0.5% Triton X‐100 for 48 h at 4°C. .. After washing in TBS, the sections were incubated in biotinylated rabbit anti‐goat IgG (H + L) Article Title: Neonatal Hyperoxia Induces Metabolic Reprogramming in Senescent Alveolar Macrophages, Leading to Persistent Lung Injury Article Snippet: Samples were incubated overnight at 4 °C with primary antibodies against Pdh E1 subunit α1 (Pdha1, ab168379, Abcam, Cambridge, MA, USA, 1:100 dilution), NOS2 (PA1-036, ThermoFisher, Waltham, MA, USA, 1:50 dilution), Syk (PA5-96063, ThermoFisher, 1:100 dilution), transferrin receptor (ab84036, Abcam, 1:100 dilution), or CD68 (ab283654, Abcam, 1:100 dilution), co-staining with lamin B1 (MA1-06103, ThermoFisher, 1:100 dilution) and p21 (MA5-31479, ThermoFisher, 1:100 dilution) as senescence biomarkers. .. After incubation with goat-anti mouse (A-11001, ThermoFisher) or goat-anti-rabbit (A-11012, ThermoFisher) secondary antibodies (1:5000, 1 h, room temperature), sections were mounted in 4′,6-diamidino-2phenylindole (DAPI)-containing Article Title: Neonatal Hyperoxia Induces Metabolic Reprogramming in Senescent Alveolar Macrophages, Leading to Persistent Lung Injury Article Snippet: Samples were incubated overnight at 4 °C with primary antibodies against Pdh E1 subunit α 1 (Pdha1, ab168379, Abcam, Cambridge, MA, USA, 1:100 dilution), NOS2 (PA1–036, ThermoFisher, Waltham, MA, USA, 1:50 dilution), Syk (PA5–96063, ThermoFisher, 1:100 dilution), transferrin receptor (ab84036, Abcam, 1:100 dilution), or CD68 (ab283654, Abcam, 1:100 dilution), co-staining with lamin B1 (MA1–06103, ThermoFisher, 1:100 dilution) and p21 (MA5–31479, ThermoFisher, 1:100 dilution) as senescence biomarkers. .. After incubation with goat-anti mouse (A-11001, ThermoFisher) or goat-anti-rabbit (A-11012, ThermoFisher) secondary antibodies (1:5000, 1 h, room temperature), sections were mounted in 4′,6-diamidino-2-phenylindole (DAPI)-containing Article Title: BTG1 Acts as a Critical Tumor Suppressor Link Between HDAC Inhibition and β-Catenin Signaling Suppression in Diffuse Large B-Cell Lymphoma. Article Snippet: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive hematologic malignancy with complex pathogenesis and unsatisfactory clinical outcomes.. Although histone deacetylase inhibitors (HDACis) have demonstrated therapeutic potential, the molecular mechanisms linking epigenetic regulation to key oncogenic signaling pathways remain incompletely understood.. In this study, B‐cell translocation gene 1 (BTG1) was identified as a critical tumor suppressor that is epigenetically upregulated by HDAC inhibition in DLBCL cells. |
